SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Merck -- Ignore unavailable to you. Want to Upgrade?


To: John Carragher who wrote (926)7/14/1998 11:13:00 AM
From: tommysdad  Read Replies (1) | Respond to of 1580
 
MRK's corporate structure is completely anti-merger. It would definitely be a bad thing (long term at least) for them to merge with anyone.

If you want to look at merger opportunities, look at all the other multi-name pharmas who have already shown a propensity for growth via merger:

Glaxo-Wellcome, SmithKline Beecham, Bristol Myers Squibb, American Home Products (Wyeth, Lederle, American Cyanamid), Novartis, etc.